Clinical Trials Logo

Rhinosinusitis Acute clinical trials

View clinical trials related to Rhinosinusitis Acute.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04703673 Completed - Bronchitis Clinical Trials

Sinolpan® Pharmacy Non-interventional Study - Quality of Live

Start date: January 8, 2021
Phase:
Study type: Observational

This non-interventional study investigates the Quality of Life of patients suffering from rhinosinusitis. Patients who seek advice in a pharmacy and choose to intake Sinolpan® or Sinolpan® forte or to use nasally applied α-sympathomimetics can participate in this anonymous patient survey.

NCT ID: NCT04642989 Completed - Clinical trials for Rhinosinusitis Acute

The Effect of Facial Effleurage on Acute Rhinosinusitis

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

Rhinosinusitis accounts for 12% of the total antibiotic prescriptions filled in the United States annually; however, the majority of rhinosinusitis cases have been proposed to have a viral etiology, or are capable of spontaneously resolving. This overuse of antibiotics is contributing to the development of antibiotic-resistant human pathogenic bacteria, and increasing patient mortality to previously easily cured diseases. This is also causing an unnecessary financial burden especially for uninsured, rural families. Facial Effleurage (FE) is an osteopathic manipulative therapy that allows physicians an alternative therapy to prescribing antibiotics; however, the only scientific literature on the technique is weak in design and execution. This will be a randomized, placebo-controlled clinical trial to test the ability of FE to reduce symptom severity over time, reduce the cellular infiltrate into the nasal cavity, and to more quickly resolve the symptoms of rhinosinusitis compared to antibiotic treatment. This methodical approach to the efficacy of FE has the potential to impact the treatment recommendations of physicians immediately, and to convince more physicians to prescribe less antibiotics and rely more heavily on FE.